Prognostic factors in patients with hepatitis B virus‑related hepatocellular carcinoma undergoing nucleoside analog antiviral therapy

  • Authors:
    • Hiroki Nishikawa
    • Norihiro Nishijima
    • Akira Arimoto
    • Tadashi Inuzuka
    • Ryuichi Kita
    • Toru Kimura
    • Yukio Osaki
  • View Affiliations

  • Published online on: September 12, 2013     https://doi.org/10.3892/ol.2013.1578
  • Pages: 1213-1218
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

In the present era of entecavir (ETV) use for chronic hepatitis B (CHB), the prognostic factors in hepatitis B virus (HBV)‑related hepatocellular carcinoma (HCC) remain unclear. The aims of the present study were to investigate the prognostic factors in patients with HBV‑related HCC treated with ETV who underwent curative therapy. A total of 74 HBV‑related HCC patients treated with ETV who underwent curative therapy were analyzed. Predictive factors associated with overall survival (OS) and recurrence‑free survival (RFS) were examined using univariate and multivariate analysis. Our study population included 49 males and 25 females with a median age of 62 years. The median observation period was 3.4 years (range, 0.2‑11.5 years). The 1‑, 3‑ and 5‑year cumulative OS rates were 100, 89.8 and 89.8%, respectively. The corresponding RFS rates were 82.8, 52.1 and 25.6%, respectively. In this study, 73 patients (98.6%) achieved an HBV DNA level of <400 copies/ml during the follow‑up period. No viral breakthrough hepatitis, as defined by 1 log increase from nadir, was observed during ETV therapy. According to multivariate analysis, only hepatitis B e antigen (HBeAg) positivity was significantly associated with OS [hazard ratio (HR), 0.058; 95% confidence interval (CI), 0.005‑0.645; P=0.020)], whereas HCC stage (HR, 0.359; 95% CI, 0.150‑0.859; P=0.021), HBeAg positivity (HR, 0.202; 95% CI, 0.088‑0.463; P<0.001) and γ‑glutamyl transpeptidase ≥50 IU/l (HR, 0.340; 95% CI, 0.152‑0.760; P=0.009) were significant predictive factors linked to RFS. In conclusion, HBeAg positivity was significantly associated with OS and RFS in HBV‑related HCC patients treated with ETV who underwent curative therapy. In such patients, close observation is required, even after curative therapy for HCC.
View Figures
View References

Related Articles

Journal Cover

November 2013
Volume 6 Issue 5

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Nishikawa H, Nishijima N, Arimoto A, Inuzuka T, Kita R, Kimura T and Osaki Y: Prognostic factors in patients with hepatitis B virus‑related hepatocellular carcinoma undergoing nucleoside analog antiviral therapy. Oncol Lett 6: 1213-1218, 2013
APA
Nishikawa, H., Nishijima, N., Arimoto, A., Inuzuka, T., Kita, R., Kimura, T., & Osaki, Y. (2013). Prognostic factors in patients with hepatitis B virus‑related hepatocellular carcinoma undergoing nucleoside analog antiviral therapy. Oncology Letters, 6, 1213-1218. https://doi.org/10.3892/ol.2013.1578
MLA
Nishikawa, H., Nishijima, N., Arimoto, A., Inuzuka, T., Kita, R., Kimura, T., Osaki, Y."Prognostic factors in patients with hepatitis B virus‑related hepatocellular carcinoma undergoing nucleoside analog antiviral therapy". Oncology Letters 6.5 (2013): 1213-1218.
Chicago
Nishikawa, H., Nishijima, N., Arimoto, A., Inuzuka, T., Kita, R., Kimura, T., Osaki, Y."Prognostic factors in patients with hepatitis B virus‑related hepatocellular carcinoma undergoing nucleoside analog antiviral therapy". Oncology Letters 6, no. 5 (2013): 1213-1218. https://doi.org/10.3892/ol.2013.1578